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Background: Late intestinal toxicity after radiotherapy (LITAR) not only limits the radiation dose, which
subsequently leads to unfavorable clinical outcomes, but also significantly lowers the quality of life in an increasing
number of cancer survivors. Therefore, identifying clinical risk factors for LITAR is important for establishing a
predictive model in the clinical setting of decision-making for these patients. This review aims to systematically
summarize and clarify the clinical factors that can be potentially associated with an increased risk of moderate/
severe LITAR in patients with abdominal or pelvic malignancies.
Methods/design: MEDLINE, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, Scopus,
Google Scholar and Chinese BioMed will be systematically searched to identify appropriate studies. Citations of the
retrieved studies and recent reviews will also be searched separately by case.
The enrolled studies should at least have the following information: (1) a clear definition and information on the
LITAR severity; (2) assess clinical factors for moderate/severe toxicity with adjusted risk estimates; (3) have a cohort,
case–control, randomized controlled trial and controlled clinical trial study design.
Two authors will independently review the abstract and full text of retrieved studies, extract data from eligible
studies and assess the risk of bias. Disagreements will be discussed among reviewers until a consensus is reached.
The effect of identified risk factors will be displayed in forest plots. If the information is sufficient, results will be
synthesized by a meta-analysis with the random effects model to pool the estimate of risk posed by clinical factors.
Subgroup and sensitivity analysis will be used to explore the sources of heterogeneity.
Discussion: This review will summarize the evidence of clinical risk factors for moderate/severe LITAR. The results
may help guide decision-making and minimize the side effects of therapeutic modalities in the clinical setting.
Trial registration: This review has been registered at PROSPERO. The registration no. is CRD42013003744.
Keywords: Intestinal toxicity, Radiation injury, Radiotherapy adverse effect, Risk factor, Chronic radiation enteritis,
Systematic reviewBackground
Radiotherapy is one of the most effective management
methods for solid malignancies. It is estimated that
about 50% of all cancer patients will receive radiotherapy
in the course of treatment for the disease [1]. Data from
the International Agency for Research on Cancer (IARC)
indicates that there are about 12.7 million new cancer
cases per year worldwide. Among those patients, more
than 5.2 million suffer from either abdominal or pelvic* Correspondence: leiwangyinghu@hotmail.com
1Department of Colorectal Surgery, Sixth Affiliated Hospital, Sun Yat-sen
University, 26 Yuancun Er Heng Road, Guangzhou 510655Guangdong, P.R.
China
Full list of author information is available at the end of the article
© 2013 Qin et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormalignancies [2,3]. Studies have showed that 14−68% of
patients with abdominal or pelvic cancers eventually
undergo radiotherapy for either curative or palliative
care [1]. There is no doubt that radiotherapy accompan-
ied by other therapeutic modalities has greatly contri-
buted to increased long-term survival rates for these
patients, although treatment-associated toxicities are
commonly found [4-6].
Late intestinal toxicity after radiotherapy (LITAR) for
abdominal or pelvic cancers, resulting from exposure of
the nontarget bowel area and irreversible progression of
lesions, could not be averted even by the most advanced
radiation techniques [6-8]. LITAR, sometimes called. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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major intestinal toxicities or complications occurring or
persisting more than 3 months after radiotherapy.
Potential symptoms include significant diarrhea, consti-
pation, distention, abdominal or bottom pain, rectal
bleeding and complications of fecal incontinence, bowel
obstruction and fistulas [7-10]. The prevalence of LITAR
varies across studies depending on the grading criteria,
time of follow-up and study design. Of note, about
80−90% of patients who have undergone abdominal or
pelvic radiotherapy will develop a permanent change in
bowel habits, and the quality of life of half of these pa-
tients will be affected [10-12]. Despite the high incidence
of mild symptoms, it is commonly recognized that the
incidence of moderate/severe LITAR is 5.6−15% [13-17].
Moderate/severe LITAR not only limits the radiation
dosage and target effect, but also significantly lowers the
quality of life of cancer survivors [5,18]. It is essential to
strike a balance between the therapeutic benefits and
side effects of radiotherapy. Unfortunately, the early
symptoms of LITAR, without enough specificity, are
often masked by drug effects or other gastrointestinal
diseases [7,19]. Moreover, the separate patterns of mod-
ern cancer therapy prevent doctors in different fields
from having an overview of patients’ conditions, further
obscuring the diagnosis and treatment strategy for
LITAR [7,9]. Therefore, it is imperative to identify risk
factors for developing moderate/severe LITAR that
could be pivotal in recognizing potential patient popula-
tions that are more likely to have side effects versus who
are not prior to the administration of radiotherapy.
Previous studies have focused on investigating radi-
ation dosimetric factors that play a direct role in the
development of intestinal injuries, aiming to establish a
predictive model of Normal Tissue Complication Pro-
bability (NTCP) with radiation parameters [20-23].
Genetic profiling is another promising tool for risk
stratification of these patients, which is supported by
that fact that some studies have verified gene markers
for patients who are predisposed to radiotherapy-
associated side effects [5,24-26]. However, these findings
need further confirmation by independent studies and
multicenter clinical trials [5,27,28].
On the other hand, clinical characteristics might be
alternative factors that can predict the outcomes of
treatments. Clinical factors, such as general physical
condition, lifestyle, accompanying diseases, and relevant
therapy, among others, account for much of the vari-
ation in normal tissue reactions to radiation and affect
the outcomes of patients after radiotherapy [7,29]. Con-
sequently, developing a practical and useful prediction
model using clinical risk factors for oncologists, radio-
therapists, and gastroenterologists would be a signifi-
cant contribution. Increasingly, studies are describingthe clinical risk factors for moderate/severe LITAR
[15,30-33]. Nevertheless, the findings from many studies
are still controversial [7]. To date, no systematic review
has summarized the clinical risk factors that are poten-
tially associated with LITAR. Thus, in this study, we
conducted a systematic review to summarize and cla-
rify which clinical factors are associated with an in-
creased risk of moderate/severe LITAR in patients
who have undergone radiotherapy for pelvic or ab-
dominal malignancies.
Methods/design
We will follow the recommendations made by Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [34] and the Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) group
[35] throughout the course of this review. The PRISMA
and MOOSE checklists are described in detail in
Additional file 1. Ethics is not required given the
protocol is for a systematic review.
This review has been registered at PROSPERO. The
registration no. is CRD42013003744.
Data sources
Electronic databases and clinical trials registries will be
searched. MEDLINE, EMBASE, Web of Science, Cochrane
Central Register of Controlled Trials (CENTRAL), Scopus,
Google Scholar and Chinese BioMed (CBM) from 1990 to
2013 will be systematically searched. Since the well-
accepted radiation toxicity criteria were initially published
in the 1990s [36,37], studies from before that time are not
comparable with others because of the different definition
and grading system used. Moreover, multivariate analysis
and analysis adjusted for confounding factors were seldom
used before the 1990s, which could potentially cause an
additional bias by chance. Therefore, we will focus on
studies that were carried out after 1990. In addition, we
will also look through the citations in the retrieved studies
and recent reviews to avoid missing relevant studies in
this field.
Search strategy
In conjunction with a librarian (QH) and a researcher
with experience in systematic reviews (RZ), we devel-
oped a systematic search strategy with structured terms
of medical subject headings (MeSH) and free keywords.
Three themes will be searched for, including “radiation
toxicity,” “intestinal diseases and symptoms,” and “radio-
therapy for abdominal or pelvic malignancy.” There is no
restriction on the study language. The search strategy for
MEDLINE in PubMed is described in detail in Additional
file 2, which will be adjusted to search for eligible studies
in other databases as well.
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Studies will be included if they fulfilled the following
criteria.
Population of interest
Included studies should target populations with primary
diseases that require pelvic radiotherapy, including:
1. Genitourinary malignancies of males and females,
such as prostate cancer, bladder cancer, cervical
cancer, endometrial cancer, etc.;
2. Gastrointestinal malignancies, such as colorectal
cancer, anal cancer, etc.;
3. Other malignant diseases that require abdominal or
pelvic radiotherapy, such as non-Hodgkin’s
lymphoma, etc.
Of note, studies only on animals will be excluded.
Risk factors of interest (intervention/exposure)
Included studies should assess at least one clinical risk
factor other than radiation dosimetric variables. Clinical
risk factors include patients’ demographics (race, ethni-
city, age, BMI, education level, economic status), lifestyle
(alcohol use, smoking), history of pre-radiation medical
disorders and gastrointestinal symptoms, accompanying
diseases (diabetes, hypertension, cardiovascular disease),
concomitant treatments (chemotherapy, hormone therapy)
and acute radiation-induced intestinal toxicity.
Comparators
Comparator groups of cohort and intervention studies
should be set with the same primary diseases and com-
parable radiation plans, but without specific risk factors.
For case–control studies, comparator groups should be
populations that received radiotherapy for the same pri-
mary diseases but did not have moderate/severe LITAR.
Study outcomes
The primary outcome of this review is moderate/severe
LITAR. Studies describing risk factors for LITAR with-
out grading or only measuring mild symptoms will be
excluded. In addition, only studies providing risk esti-
mates adjusted for at least one confounding factor will
be included.
Included studies should use a similar definition of
LITAR, which is major intestinal toxicities or complica-
tions occurring or persisting more than 3 months after
radiotherapy [7-10]. The severity of LITAR should be
evaluated in accordance with the Radiation Therapy
Oncology Group/European Organization for Research
and Treatment of Cancer (RTOG/EORTC) scoring scale
[36,38] or Common Terminology Criteria for Adverse
Events (CTCAE) from the National Cancer Institute[39]. Self-reported symptoms should be assessed on the
basis of Late Effects in Normal Tissues Subjective, Objec-
tive, Management and Analytic (LENT SOMA) scales,
incorporated into CTCAE [37,40]. Grade 2 and higher
according to RTOG/EORTC or LENT SOMA/CTCAE
will be considered to be moderate/severe.
Study designs
Observational cohort and case–control studies, random-
ized controlled trials (RCTs) and controlled clinical trials
(CCTs) for interventions will be included. Cross-sectional
studies, case series, case reports, experimental studies and
reviews will be excluded.
Study selection
Two reviewers (QZ, ZY) will separately and independ-
ently screen the titles and abstracts of studies identified
from initial searches. A standard screening checklist
based on the eligibility criteria above will be employed
for each study. Studies that do not meet the criteria
according to the titles or abstracts will be excluded. Full-
text versions of the remaining studies, including those
that are potentially eligible studies and uncertain, will be
retrieved for a second review by at least two reviewers
(QZ, ZY, QQ) independently to determine the eligibility.
Disagreements with regard to study eligibility will be fur-
ther discussed among reviewers. If consensus cannot be
reached, a third reviewer (LW) will make the ultimate
decision.
For studies without sufficient information to evaluate
the eligibility, we will contact the study authors via
email to obtain their clarifications. The studies will be
excluded if there is still insufficient information after
this contact.
If more than one publication reports the results from
the same study population, we will choose the publica-
tion with the largest sample size. The abstracts that
were published in academic conferences will be evalu-
ated by case, and we will contact the study authors for
details if necessary. The abstracts or full texts of studies
not published in English will be translated by Google
Translate. If the information is unclear, we will refer to
professional translations.
Data extraction
We will develop three kinds of data extraction form corre-
sponding to different study designs. There will be specific
forms for cohort studies, case–control studies, and RCTs
or CCTs. The data extraction form used for cohort studies
is described in detail in Additional file 3.
The data items mainly abstracted are as follows: title,
first author, year of publication, publication journal,
funding source and conflict of interest, trial code desig-
nation, study design (prospective, retrospective), study
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study period, sample size, control conditions, interven-
tions/exposures, randomization, blinding), study popula-
tion and patient demographics (gender ratio, patients
age range, race and ethnicity), radiation instrument,
radiotherapy plan (total dose, external beam radiation
dose, brachytherapy dose, dose fractionation, target area
arrangement) and results (follow-up period, number of
patients lost to follow-up, number of cases, identified
risk factors, adjusted effect estimates and 95% CI). We
will extract or calculate the adjusted estimates of the
odds ratio (OR), rate ratio (RR), hazard ratio (HR) for
factors of interest and associated 95% CIs from eli-
gible studies.
Two review authors (QZ, ZY) will separately and in-
dependently extract the data from the eligible studies.
Disagreements regarding the data extraction between
authors will be resolved by discussion. If consensus can-
not be reached, a third author (LW) will review the
study and arbitrate. If data are missing for synthesis or
assessment of study quality, we will attempt to contact
the study authors via email at least two times. The study
will be excluded if there is still insufficient data following
this process.Assessment of quality (risk of bias)
The study characteristics regarding the risk of bias will be
extracted to evaluate study quality by two review authors
(RZ, QQ) independently. Disagreement between authors
in respect of study quality assessment will be resolved
by discussion.
The assessment items for cohort studies, as outlined
in the Newcastle-Ottawa scale [41], include cohort selec-
tion (representativeness of the exposed cohort and non
exposed cohort, ascertainment and timing of the expos-
ure), comparability and outcome measure (assessment
method, time and adequacy of follow-up). The assess-
ment items for case–control studies, as outlined in the
Newcastle-Ottawa scale [41], include case selection (def-
inition and representativeness of cases and controls),
comparability and exposure measure (assessment
method, parallel between cases and controls, response
rate). The assessment items, outlined in the Cochrane
Collaboration’s tool for assessing the risk of bias for
RCTs [42], include the method of randomization, con-
cealment of treatment allocation, blinding of patients
and researchers throughout the trial (intervention, data
collection and analysis), completeness of outcome data,
selective report of outcomes and any other potential
sources of bias. There is no special tool to assess the risk
of bias for CCTs, which will be evaluated based on
blinding, comparability, completeness of outcome data
and selective report of outcomes.The levels of assessment items will be displayed for each
eligible study accompanying the published manuscript.Statistical analysis
Data synthesis and analysis
The effects of risk factors will be explored in forest
plots. A meta-analysis will be applied to each factor if
the definitions of outcomes and characteristics among
studies are comparable. Because the incidence of mod-
erate/severe LITAR is relatively low, we consider that
the estimate of OR could approximate the estimate of
relative risk (RR, HR). Subsequently, we will use OR
as the effect measure for meta-analysis in the current
review [43].
The effect of residual confounding factors is an un-
avoidable limitation of meta-analyses of observational
studies. Therefore, we will use the random effects model
of Dersimonian and Laird [44] to pool the overall ad-
justed OR and associated 95% CI, based on our assump-
tion that there is potential variation among studies of
different populations, designs, primary malignancies and
radiation plans.
Different risk factors are confounders to each other. If
the information is sufficient, the pooling estimate of one
factor will be adjusted for other potential risk factors.Assessment of heterogeneity
Heterogeneity across all the studies will be assessed by
the Cochran Q test and I2 statistic. The latter could
reflect the magnitude of between-study variation attrib-
uted to heterogeneity, which is preferred with an in-
creased number of included studies [45].
Subgroup analysis will be further used to explore the
sources of heterogeneity. When data are sufficient, sub-
groups will be stratified as follows: study population,
study design (prospective vs. retrospective), regions of
intestinal toxicity (colorectum vs. small intestine), pri-
mary malignancies and radiation instruments.
We will also perform sensitivity analysis to assess the
robustness of results with variation in study quality, time
of follow-up, effect measures (OR/ RR) and severity
of LITAR.Assessment of publication bias
The results will be displayed in forest plots and cumulative
forest plots, which provide a visual and direct impression
of effect size and publication bias. We will also perform
Peters’ regression analysis to assess the trend with a funnel
plot [46].
StataSE (version 11.0; StataCorp, College Station, TX)
will be used for data synthesis, assessment of heterogeneity
and publication bias.
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This systematic review will summarize the evidence of
clinical risk factors for moderate/severe late intestinal
toxicity in patients who have undergone abdominal or
pelvic radiotherapy. In summary, patients’ demographics,
lifestyles, history of previous medical disorders, concur-
rent diseases and concomitant treatment will be taken
into account. The enrolled studies for this review will in-
clude cohort studies, case–control studies, RCTs and
CCTs. A meta-analysis will also be used to explore the
estimate of risk factors if necessary.
The finding of this review will be widely disseminated
through peer-reviewed publications, conference presen-
tations and other health information press sources. This
will provide comprehensive information that might be of
importance with regard to individualized treatment of
malignancies and will help to archive the early detection
of major LITAR. In light of specific clinical risk factors,
health care providers could inform and discuss with
patients to make optimized clinical decisions, ultim-
ately leading to averting unnecessary suffering and eco-
nomic losses.
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